First human tests begin for new Weight-Loss and diabetes drug
NCT ID NCT06945419
Summary
This is an early-stage study to check the safety and how the body processes a new drug called LY4086940. It will involve about 201 healthy people and people who are overweight, have obesity, or have type 2 diabetes. The main goal is to see if the drug is safe and well-tolerated at different dose levels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Pharmacology of Miami
NOT_YET_RECRUITINGMiami, Florida, 33172, United States
Contact Phone: •••-•••-••••
Contact
-
Endeavor Clinical Trials
RECRUITINGSan Antonio, Texas, 78240, United States
Contact Phone: •••-•••-••••
Contact
-
Fortrea Clinical Research Unit
RECRUITINGDaytona Beach, Florida, 32117, United States
Contact Phone: •••-•••-••••
Contact
-
Fortrea Clinical Research Unit
RECRUITINGDallas, Texas, 75247, United States
Contact Phone: •••-•••-••••
Contact
-
Lilly Centre for Clinical Pharmacology
COMPLETEDSingapore, 138623, Singapore
Conditions
Explore the condition pages connected to this study.